How Can Specialty Pharmacies Reduce the Cost of Orphan Drugs?

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, discusses the role specialty pharmacies play in helping patients manage drug costs.

Joy Gilbert: It’s interesting, because specialty pharmacies do have a role to play related to cost in orphan products, but as most people in the industry know, the pharmacy doesn’t actually set the price of the product. So it’s our job really to help patients navigate through their own financial barriers related to understanding their insurance benefits, identifying resources for copay assistance and out of pocket burdens that the patient might bear. But we as a pharmacy industry are working within a narrow constraint of product acquisition cost and insurance reimbursement.


Most Popular

Related Articles

Top news of the week from Specialty Pharmacy Times.
Olaparib (Lynparza, AstraZeneca and Merck), which is being investigated for the treatment of prostate cancer, receives its fourth orphan drug designation from the FDA.
Specialty medications are still mostly branded products, but patients remain hesitant to accept less expensive generic alternatives when the option is available.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.